On 17 January 2025, the FDA approved Dato-DXd for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who had received prior endocrine-based therapy and chemotherapy [14]. Here, ERBB2 is linked to breast carcinoma.